Boston Scientific is Wednesday's pick for IBD 50 Growth Stocks To Watch. The medical device maker is wavering around the buy point of a double-bottom base for its fourth straight session.
Boston Scientific moved higher after the company's positive earnings report in late April. Shares were relatively flat Wednesday.
The IBD 50 and IBD Leaderboard name makes technology and devices for heart-rhythm, cardiovascular and neurological disorders. It ranks No. 1 out of 123 stocks in the Medical-Products group, which holds the 65th spot out of the 197 industry groups that Investor's Business Daily tracks.
Boston Scientific executives are scheduled to participate in a question-and-answer session at Bank of America's 2025 Health Care Conference on May 13.
How To Know It's Time To Sell Your Favorite Stock
Boston Scientific Stock Wavers Near Buy Point
The medical device stock first broke out of an early-stage double-bottom base Friday with a 104.35 buy point, according to MarketSurge pattern recognition. But shares fell back below the entry Monday and have hovered around it since. The stock is nearing an all-time high of 107.17, reached Feb. 5.
Shares have gained around 16% so far this year vs. the S&P 500's loss of around 4%. Its relative strength line has been steadily climbing since October 2023.
Its volume has been trending lighter than average since its 4.1% jump following the earnings report on April 23. Boston Scientific stock retook its 50-day moving average following the earnings report.
Medical Device Maker Has Beat-And-Raise Quarter
Boston Scientific topped first-quarter earnings and sales estimates April 23. It also raised its full-year 2025 profit outlook to a range of $2.87 to $2.94 per share, and now expects net sales to increase 15% to 17%.
Earnings growth accelerated for three straight quarters to 34% in the first quarter. Sales have increased an average 20% over the last three quarters, which was an improvement over the average 14% in the prior three quarters. Estimates call for 19% revenue growth in the second quarter, then a decline to 11% over the next four quarters.
Analyst projections show 2025 per-share earnings of $2.92, or 16% growth. For 2026, Boston Scientific's earnings are expected to increase 13% to $3.29 per share. The company's IBD Earnings Per Share Rating is a robust 96. Finally, Boston Scientific holds a best-possible 99 Composite Rating.
Boston Scientific has been a steady profit grower as seen in its Earnings Stability factor of 11 out of 99 possible — with a lower number being better.
Mutual funds have added Boston Scientific stock for eight straight quarters, with 3,764 owning shares in March, up from 3,688 in December. And four IBD Mutual Fund Index names hold the medical device stock, including Fidelity Contrafund, with an 8.39 million share position as of March.
Follow Kimberley Koenig for more stock market news on X, the platform formerly known as Twitter, @IBD_KKoenig.
